Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022027058 - METHODS OF TREATING MUTANT LYMPHOMAS

Publication Number WO/2022/027058
Publication Date 03.02.2022
International Application No. PCT/US2021/071048
International Filing Date 29.07.2021
IPC
A61K 31/4545 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 47/55 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
55the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 277/60 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
277Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60condensed with carbocyclic rings or ring systems
C07D 417/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
CPC
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • KYMERA THERAPEUTICS, INC. [US]/[US]
Inventors
  • WALKER, Duncan
Agents
  • REID, Andrea, L. C.
  • ARICO, Joseph, W.
  • FLEMING, Paul, R.
  • NIHAN, Danielle, M.
  • WANG, Gang
  • DAVIS, Chad, E.
  • STEVENSON, Christian, P.
  • MANAS, Michael
  • MACKLIN, Todd, K.
  • ANDERSON, Kurtis, M.
  • GARRIDO, Hugo
  • WILKINS, Andrew, T.
  • COUGHLIN, Sean, M.
  • BRESE, Robin, L.
  • BUCCI, Michael, D.
Priority Data
63/058,89130.07.2020US
63/109,85404.11.2020US
63/202,24202.06.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING MUTANT LYMPHOMAS
(FR) PROCÉDÉS DE TRAITEMENT DE LYMPHOMES MUTANTS
Abstract
(EN) The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders.
(FR) La présente invention concerne des procédés de traitement de lymphomes des lymphocytes B mutants MYD88 à l'aide d'agents de dégradation de IRAK4.
Latest bibliographic data on file with the International Bureau